A review by Astarini et al. (2022) reported that IL17A polymorphisms contribute to hepatic steatosis, inflammation, and fibrosis, further supporting genetic involvement in MASLD [39]. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.